Novacyt Stock OTC Markets
Stocks
NVYTF
FR0010397232
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
OTC Markets
09:30:11 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 0.5705 USD | -.--% |
|
-.--% | +11.84% |
| 09-08 | EARNINGS AND TRADING: Acuity eyes 'breakeven' as loss narrows | AN |
| 09-08 | Novacyt S.A. Launches IVDR-Certified Yourgene Insight DPYD Assay | CI |
| Market Cap | 33.79M 37.58M 31.53M 28.58M 53.65M 3.58B 53.98M 378M 148M 1.86B 141M 138M 5.97B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 35.74M 39.75M 33.35M 30.23M 56.76M 3.78B 57.11M 400M 156M 1.96B 149M 146M 6.31B | EV / Sales 2026 * |
1.17x | EV / Sales 2027 * | 1.11x |
| Free-Float |
99.83% | Yield 2026 * |
-
| Yield 2027 * | - |
OTC MarketsUSD
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALNOV | Real-time | |
London S.E.
| NCYT | Delayed | |
CBOE
| Real-time | ||
OTC Markets
| NVYTF | Delayed | |
Tradegate
| NYZ | Real-time | |
CBOE
| NCYT | Real-time | |
Deutsche Boerse AG
| NYZ | Delayed | |
Börse Stuttgart
| NYZ | Delayed | |
Boerse Muenchen
| NYZ | Real-time | |
CBOE
| NCYT | Real-time |
Last Transcript: Novacyt
| 09-30 | Novacyt : Interim Accounts June 2026 (EN) | PU |
| 09-30 | Novacyt : Rapport DActivité Semestriel 2026 (EN) | PU |
| 04-30 | Novacyt : 2025 Management Report | PU |
| 04-30 | Novacyt : 2025 Group Consolidated Accounts | PU |
| 25-10-22 | Novacyt : NCYT Re-launch Investor Film | PU |
| 3 months | +18.85% | ||
| 6 months | +18.85% | ||
| Current year | +11.84% |
| Current year | 0.48 | 0.57 | |
| 1 year | 0.48 | 0.57 | |
| 3 years | 0.48 | 1.25 | |
| 5 years | 0.48 | 5.77 | |
| 10 years | 0 | 16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lyn Rees
CEO | Chief Executive Officer | 53 | 2024-04-30 |
Steven Gibson
DFI | Director of Finance/CFO | 44 | 2019-12-31 |
Peter Coyne
COO | Chief Operating Officer | - | 2021-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2006-07-02 | |
Juliet Thompson
BRD | Director/Board Member | 60 | 2017-06-26 |
Steven Gibson
BRD | Director/Board Member | 44 | 2024-01-01 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | - | - | 37.82M | ||
| -2.01% | -7.86% | +54.60% | +70.97% | 70.44B | ||
| +3.84% | -11.02% | +8.59% | +58.77% | 50.31B | ||
| +3.35% | +1.42% | +11.85% | +37.39% | 47.51B | ||
| +0.51% | +1.72% | +28.23% | +31.95% | 42.91B | ||
| +3.34% | -2.97% | +310.32% | +471.22% | 40.39B | ||
| +1.13% | -3.18% | +9.81% | +102.62% | 39.69B | ||
| +0.06% | -1.43% | +10.47% | +43.27% | 30.59B | ||
| -2.95% | -14.09% | +37.94% | +1.30% | 26.8B | ||
| +0.33% | -6.68% | -13.37% | -8.33% | 22.36B | ||
| Average | +0.76% | -5.58% | +50.94% | +89.90% | 41.22B | |
| Weighted average by Cap. | +0.91% | -5.44% | +53.94% | +95.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.52M 33.95M 28.49M 25.82M 48.47M 3.23B 48.77M 342M 133M 1.68B 127M 125M 5.39B | 34.86M 38.77M 32.53M 29.49M 55.36M 3.69B 55.7M 390M 152M 1.92B 146M 142M 6.16B |
| Net income | - | - |
| Net Debt | 1.96M 2.18M 1.83M 1.65M 3.11M 207M 3.13M 21.91M 8.55M 107M 8.17M 7.99M 346M | 4.84M 5.39M 4.52M 4.1M 7.69M 512M 7.74M 54.23M 21.17M 266M 20.22M 19.78M 855M |
Employees
228
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ALNOV Stock
- NVYTF Stock
Select your edition
All financial news and data tailored to specific country editions

















